Eli Lilly and Company (LLY)
Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve
Eli Lilly shed billions in market value over the past month while its underlying business kept breaking records, and now one major Wall Street firm sees a setup that almost never appears in a stock this dominant.
People are taking bootleg versions of an Eli Lilly drug that isn't approved yet. Ohio wants it to stop.
As bootleg versions of an experimental drug from Eli Lilly flood the market, regulators are trying to curb supply.
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.
Eli Lilly hasn't split its stock in nearly 30 years, but as shares trade above $1,000, the pharmaceutical company could be considering one. Considering other high-profile stock splits in recent years, count on company-specific catalysts, not the split itself, to drive further gains.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline
Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, part of a deal-making push to broaden its treatments for immune-related and allergic diseases. The acquisition continues a run of dealmaking for Lilly, whose deal spending this year has outpaced prior years as it looks to diversify beyond its blockbuster obesity and diabetes franchises.
LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock.
Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions.
Eli Lilly to Buy Merida Biosciences For Up to $2.875 Billion
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker's immunology portfolio.
